Investors sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on strength during trading hours on Friday. $183.13 million flowed into the stock on the tick-up and $207.02 million flowed out of the stock on the tick-down, for a money net flow of $23.89 million out of the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 0th highest net out-flow for the day. Regeneron Pharmaceuticals traded up $11.61 for the day and closed at $373.47
Several equities analysts have recently issued reports on the company. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $480.00 to $380.00 in a research report on Friday. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday. BTIG Research lowered their price target on Regeneron Pharmaceuticals from $520.00 to $480.00 and set a “buy” rating for the company in a research report on Tuesday. BMO Capital Markets set a $444.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, November 27th. Finally, Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a research report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $467.84.
The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $40,130.00, a PE ratio of 31.69, a price-to-earnings-growth ratio of 1.44 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the previous year, the firm earned $3.13 EPS. Regeneron Pharmaceuticals’s revenue was up 23.0% on a year-over-year basis. sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current year.
In other news, SVP Robert E. Landry sold 663 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total transaction of $330,571.80. Following the completion of the sale, the senior vice president now owns 10,099 shares of the company’s stock, valued at approximately $5,035,361.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. In the last three months, insiders sold 4,352 shares of company stock valued at $2,037,772. 10.80% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after purchasing an additional 416,192 shares during the last quarter. BlackRock Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after purchasing an additional 41,406 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 2.9% during the 2nd quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock valued at $2,588,533,000 after purchasing an additional 148,962 shares during the last quarter. Harding Loevner LP increased its position in shares of Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its position in shares of Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock valued at $963,852,000 after purchasing an additional 29,252 shares during the last quarter. 69.47% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/02/investors-sell-shares-of-regeneron-pharmaceuticals-regn-on-strength-regn.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.